Mary Kay Fenton - Apr 29, 2024 Form 4 Insider Report for Cullinan Therapeutics, Inc. (CGEM)

Role
Chief Financial Officer
Signature
/s/ Jacquelyn Sumer, Attorney-in-Fact
Stock symbol
CGEM
Transactions as of
Apr 29, 2024
Transactions value $
$0
Form type
4
Date filed
4/30/2024, 09:02 PM
Previous filing
Jul 6, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Award $0 +200K $0.00 200K Apr 29, 2024 Common Stock 200K $27.12 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option represents a right to purchase a total of 200,000 shares of the Issuer's Common Stock, 25% of which will become vested and exercisable on April 29, 2025, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.